Abstract
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected around 13 million people and has caused more than 5.7 lakh deaths worldwide since December 2019. In the absence of FDA approved drugs for its treatment, only symptomatic management is done.
Methods: We attempted to uncover potential therapeutic targets of spike, helicase, and RNA dependent RNA polymerase (RdRp) proteins of the SARS-CoV-2 employing a computational approach. The PDB structure of spike and RdRp and predicted structure of helicase proteins were docked with 100 approved anti-viral drugs, natural compounds, and some other chemical compounds.
Results: The anti-SARS ligands EK1 and CID 23631927, and NCGC00029283 are potential entry inhibitors as they showed affinity with immunogenic Receptor Binding Domain (RBD) of the spike protein. This RBD interacts with Angiotensin Converting Enzyme (ACE2) receptor, facilitating the entry of virion in the host cells. The FDA approved drugs, including Nelfinavir, Saquinavir, Tipranavir, Setrobuvir, Indinavir, and Atazanavir, showed potential inhibitory activity against targeted domains and thus, may act as entry or replication inhibitor or both. Furthermore, several anti-HCoV natural compounds, including Amentoflavone, Rutin, and Tannin, are also potential entry and replication inhibitors as they showed affinity with RBD, P-loop containing nucleoside triphosphate hydrolase, and the catalytic domain of the respective protein. Dithymoquinone showed significant inhibitory potential against the fusion peptide of S2 domain. Importantly, Tannin, Dithymoquinone, and Rutin can be extracted from Nigella sativa seeds and thus, may prove to be one of the most potential anti-SARS-CoV-2 inhibitors.
Conclusion: Several potential ligands were identified with already known anti-HCoVs activities. Furthermore, as this study showed that some of the ligands acted as both entry and replication inhibitors against SARS-CoV-2, it is envisaged that a combination of either inhibitor with a dual mode of action would prove to be a much desired therapeutic option against this viral infection.
Keywords: SARS-CoV-2, spike, helicase, RdRp, virtual screening, potential inhibitors, drug repurposing, natural compounds
Coronaviruses
Title:Virtual Screening of Potential Therapeutic Inhibitors Against Spike, Helicase, and Polymerase of SARS-CoV-2 (COVID-19)
Volume: 2 Issue: 1
Author(s): Ayesha Tazeen, Farah Deeba, Aftab Alam, Rafat Ali, Romana Ishrat, Anwar Ahmed, Sher Ali and Shama Parveen*
Affiliation:
- Centre for Interdisciplinary Research in Basic Sciences, Jamia Millia Islamia, New Delhi,India
Keywords: SARS-CoV-2, spike, helicase, RdRp, virtual screening, potential inhibitors, drug repurposing, natural compounds
Abstract:
Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected around 13 million people and has caused more than 5.7 lakh deaths worldwide since December 2019. In the absence of FDA approved drugs for its treatment, only symptomatic management is done.
Methods: We attempted to uncover potential therapeutic targets of spike, helicase, and RNA dependent RNA polymerase (RdRp) proteins of the SARS-CoV-2 employing a computational approach. The PDB structure of spike and RdRp and predicted structure of helicase proteins were docked with 100 approved anti-viral drugs, natural compounds, and some other chemical compounds.
Results: The anti-SARS ligands EK1 and CID 23631927, and NCGC00029283 are potential entry inhibitors as they showed affinity with immunogenic Receptor Binding Domain (RBD) of the spike protein. This RBD interacts with Angiotensin Converting Enzyme (ACE2) receptor, facilitating the entry of virion in the host cells. The FDA approved drugs, including Nelfinavir, Saquinavir, Tipranavir, Setrobuvir, Indinavir, and Atazanavir, showed potential inhibitory activity against targeted domains and thus, may act as entry or replication inhibitor or both. Furthermore, several anti-HCoV natural compounds, including Amentoflavone, Rutin, and Tannin, are also potential entry and replication inhibitors as they showed affinity with RBD, P-loop containing nucleoside triphosphate hydrolase, and the catalytic domain of the respective protein. Dithymoquinone showed significant inhibitory potential against the fusion peptide of S2 domain. Importantly, Tannin, Dithymoquinone, and Rutin can be extracted from Nigella sativa seeds and thus, may prove to be one of the most potential anti-SARS-CoV-2 inhibitors.
Conclusion: Several potential ligands were identified with already known anti-HCoVs activities. Furthermore, as this study showed that some of the ligands acted as both entry and replication inhibitors against SARS-CoV-2, it is envisaged that a combination of either inhibitor with a dual mode of action would prove to be a much desired therapeutic option against this viral infection.
Export Options
About this article
Cite this article as:
Tazeen Ayesha , Deeba Farah , Alam Aftab, Ali Rafat , Ishrat Romana , Ahmed Anwar , Ali Sher and Parveen Shama *, Virtual Screening of Potential Therapeutic Inhibitors Against Spike, Helicase, and Polymerase of SARS-CoV-2 (COVID-19), Coronaviruses 2021; 2 (1) . https://dx.doi.org/10.2174/2666796701999200826114306
DOI https://dx.doi.org/10.2174/2666796701999200826114306 |
Print ISSN 2666-7967 |
Publisher Name Bentham Science Publisher |
Online ISSN 2666-7975 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Impact of Traditional Plants and their Secondary Metabolites in the Discovery of COVID-19 Treatment
Current Pharmaceutical Design Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?
Current Respiratory Medicine Reviews Intracellular Delivery: Exploiting Viral Membranotropic Peptides
Current Drug Metabolism Adverse Reactions and Pathogen Safety of Intravenous Immunoglobulin
Current Drug Safety Impact of COVID-19 on Gender Equality, Sexual and Reproductive Health Rights of Adolescent Girls and Young Women: A Narrative Review
Current Women`s Health Reviews Natural Substances and Semisynthetic Derivatives as Potential Alternative Products Against SARS-CoV-2
Mini-Reviews in Medicinal Chemistry SARS-CoV-2 Therapy: Old Drugs as New Interventions
Coronaviruses Mental and Emotional Wellbeing During the COVID-19 Pandemic: The Unprecedented Malaysian Experience
Current Psychiatry Research and Reviews Prediction of Infection and Death Ratio of COVID-19 Virus in Turkey by Using Artificial Neural Network (ANN)
Coronaviruses Antiviral Effects of Asian Natural Products Targeting SARS, MERS, and COVID-19
Coronaviruses Hydrogen Gas Therapy: From Preclinical Studies to Clinical Trials
Current Pharmaceutical Design Mesenchymal Stem Cell Derived-Exosomes as Effective Factors in Reducing Cytokine Storm Symptoms of COVID-19
Protein & Peptide Letters COVID-19 Infection: A Review of Summarized Clinical Trials Study for the Treatment
Coronaviruses Clinical Review of COVID-19; Pathogenesis, Diagnosis, and Management
Current Pharmaceutical Design Dental Care during the COVID-19 Pandemic
Coronaviruses Antiviral Potential of Coconut (<i>Cocos nucifera L.</i>) Oil and COVID-19
Coronaviruses Robust Modeling and Scaffold Hopping: Case Study Based on HIV Reverse Transcriptase Inhibitors Type-1 Data
Medicinal Chemistry siRNA Delivery Using Nanocarriers – An Efficient Tool for Gene Silencing
Current Gene Therapy Is There Any Role of IL-6 Inhibition in COVID-19?
Coronaviruses Indirect-Acting Pan-Antivirals vs. Respiratory Viruses: A Fresh Perspective on Computational Multi-Target Drug Discovery
Current Topics in Medicinal Chemistry